146 related articles for article (PubMed ID: 24768145)
1. Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent.
Ides J; Thomae D; Wyffels L; Vangestel C; Messagie J; Joossens J; Lardon F; Van der Veken P; Augustyns K; Stroobants S; Staelens S
Nucl Med Biol; 2014 Jul; 41(6):477-87. PubMed ID: 24768145
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of [
Vangestel C; Thomae D; Van Soom J; Ides J; Wyffels L; Pauwels P; Stroobants S; Van der Veken P; Magdolen V; Joossens J; Augustyns K; Staelens S
Contrast Media Mol Imaging; 2016 Nov; 11(6):448-458. PubMed ID: 27558262
[TBL] [Abstract][Full Text] [Related]
3. Quantitative PET Imaging of Tissue Factor Expression Using 18F-Labeled Active Site-Inhibited Factor VII.
Nielsen CH; Erlandsson M; Jeppesen TE; Jensen MM; Kristensen LK; Madsen J; Petersen LC; Kjaer A
J Nucl Med; 2016 Jan; 57(1):89-95. PubMed ID: 26383146
[TBL] [Abstract][Full Text] [Related]
4. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.
Yang D; Severin GW; Dougherty CA; Lombardi R; Chen D; Van Dort ME; Barnhart TE; Ross BD; Mazar AP; Hong H
Oncotarget; 2016 Nov; 7(45):73912-73924. PubMed ID: 27729618
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
Ross TL; Honer M; Lam PY; Mindt TL; Groehn V; Schibli R; Schubiger PA; Ametamey SM
Bioconjug Chem; 2008 Dec; 19(12):2462-70. PubMed ID: 19053298
[TBL] [Abstract][Full Text] [Related]
6. Dual mode fluorescent (18)F-PET tracers: efficient modular synthesis of rhodamine-[cRGD]2-[(18)F]-organotrifluoroborate, rapid, and high yielding one-step (18)F-labeling at high specific activity, and correlated in vivo PET imaging and ex vivo fluorescence.
Liu Z; Radtke MA; Wong MQ; Lin KS; Yapp DT; Perrin DM
Bioconjug Chem; 2014 Nov; 25(11):1951-62. PubMed ID: 25265337
[TBL] [Abstract][Full Text] [Related]
7. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
8. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of ¹⁸F-labeled BODIPY dye as potential PET agents for myocardial perfusion imaging.
Liu S; Li D; Shan H; Gabbaï FP; Li Z; Conti PS
Nucl Med Biol; 2014 Jan; 41(1):120-6. PubMed ID: 24210284
[TBL] [Abstract][Full Text] [Related]
10. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
11. [
Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of the effects of aluminum [¹⁸F]fluoride radiolabeling on an integrin αvβ₆-specific peptide.
Hausner SH; Bauer N; Sutcliffe JL
Nucl Med Biol; 2014 Jan; 41(1):43-50. PubMed ID: 24267053
[TBL] [Abstract][Full Text] [Related]
13. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of [18F]-FDEGPECO as a PET tracer for imaging the metabotropic glutamate receptor subtype 5 (mGluR5).
Wanger-Baumann CA; Mu L; Honer M; Belli S; Alf MF; Schubiger PA; Krämer SD; Ametamey SM
Neuroimage; 2011 Jun; 56(3):984-91. PubMed ID: 21406237
[TBL] [Abstract][Full Text] [Related]
15. Radiofluorinated probe for PET imaging of fatty acid binding protein 4 in cancer.
Temma T; Nishigori K; Onoe S; Sampei S; Kimura I; Ono M; Saji H
Nucl Med Biol; 2015 Feb; 42(2):184-91. PubMed ID: 25457456
[TBL] [Abstract][Full Text] [Related]
16.
Xu D; Zhuang R; You L; Guo Z; Wang X; Peng C; Zhang D; Zhang P; Wu H; Pan W; Zhang X
Nucl Med Biol; 2018 Apr; 59():48-55. PubMed ID: 29466767
[TBL] [Abstract][Full Text] [Related]
17. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
18. Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4.
Mamat C; Mosch B; Neuber C; Köckerling M; Bergmann R; Pietzsch J
ChemMedChem; 2012 Nov; 7(11):1991-2003. PubMed ID: 23042640
[TBL] [Abstract][Full Text] [Related]
19. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
20. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
